Adding Megestrol to Letrozole Enhances Antiproliferative Effects in ER+ Breast Cancer: Insights from the PIONEER Trial
Posted inHematology-Oncology news Oncology

Adding Megestrol to Letrozole Enhances Antiproliferative Effects in ER+ Breast Cancer: Insights from the PIONEER Trial

The Phase 2b PIONEER trial reveals that adding megestrol to letrozole significantly reduces tumor proliferation in early-stage ER+ breast cancer. By reprogramming estrogen receptor activity, this combination offers a dual benefit of enhanced antitumor efficacy and potential improvement in treatment adherence through hot flash mitigation.
More Is Not Always Better: Long-term Data from the SAKK 09/10 Trial Refutes Dose-intensified Salvage Radiotherapy for Prostate Cancer
Posted innews Oncology Urology

More Is Not Always Better: Long-term Data from the SAKK 09/10 Trial Refutes Dose-intensified Salvage Radiotherapy for Prostate Cancer

Long-term results from the SAKK 09/10 trial demonstrate that dose-intensified salvage radiotherapy (70 Gy) provides no oncological benefit over conventional dosing (64 Gy) in patients with biochemical recurrence after prostatectomy, while significantly increasing the risk of long-term gastrointestinal toxicity.
Optimizing Immunotherapy in Triple-Negative Breast Cancer: Reduced-Dose Folate Receptor Alpha Vaccine Shows Robust Efficacy Without Cyclophosphamide Pretreatment
Posted innews Oncology

Optimizing Immunotherapy in Triple-Negative Breast Cancer: Reduced-Dose Folate Receptor Alpha Vaccine Shows Robust Efficacy Without Cyclophosphamide Pretreatment

A Phase II trial demonstrates that a reduced-dose Folate Receptor Alpha (FRα) vaccine is safe and highly immunogenic in triple-negative breast cancer patients, achieving robust T-cell responses comparable to high-dose regimens and eliminating the need for cyclophosphamide pretreatment.
Music Therapy Proves Noninferior to Cognitive Behavioral Therapy for Managing Anxiety in Cancer Survivors: Results from a Randomized Trial
Posted inHematology-Oncology news Oncology Psychiatry

Music Therapy Proves Noninferior to Cognitive Behavioral Therapy for Managing Anxiety in Cancer Survivors: Results from a Randomized Trial

A randomized clinical trial demonstrates that telehealth-delivered music therapy is noninferior to cognitive behavioral therapy for reducing anxiety in cancer survivors, providing durable, clinically meaningful improvements and a viable alternative to traditional psychological interventions.
Functional Cure Within Reach: GSK’s Bepirovirsen Meets Primary Endpoints in Pivotal Phase III Chronic Hepatitis B Trials
Posted inGastroenterology Infectious Diseases news

Functional Cure Within Reach: GSK’s Bepirovirsen Meets Primary Endpoints in Pivotal Phase III Chronic Hepatitis B Trials

GSK has announced positive Phase III results for Bepirovirsen, an antisense oligonucleotide that achieves functional cure in chronic hepatitis B patients. By targeting viral RNA and HBsAg, the drug offers a finite treatment path, potentially transforming global hepatology standards and replacing lifelong therapy.
The Rising Burden of Sarcoidosis in England: New Evidence of Increasing Incidence and Significant Mortality Gaps
Posted innews Respiratory Rheumatology

The Rising Burden of Sarcoidosis in England: New Evidence of Increasing Incidence and Significant Mortality Gaps

A landmark study of over 18,000 patients reveals that sarcoidosis incidence and prevalence in England are rising, particularly among older adults. With a 36% higher mortality risk compared to the general population, these findings demand a shift in how the healthcare system prioritizes this complex multisystem disease.
Beyond Child Survival: The Evolving Global Burden of Lower Respiratory Infections and Emerging Pathogens (1990-2023)
Posted inInfectious Diseases news Public Health

Beyond Child Survival: The Evolving Global Burden of Lower Respiratory Infections and Emerging Pathogens (1990-2023)

The GBD 2023 study highlights a 33.4% reduction in pediatric LRI mortality since 2010, yet 2.5 million annual deaths persist. While Streptococcus pneumoniae remains the primary pathogen, newly modeled aetiologies like non-tuberculous mycobacteria now account for 22% of the total LRI mortality burden.